| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Courses and Workshops |
|
|
| |
| |
| |
September 11, 2012 |
|
|
| |
|
|
| |
|
|
|
ComplianceOnline, Online Event
2012-10-02
Why Should You Attend: Having to handle the drug needed for the conduct of a clinical trial or any other related programs (e.g. CUP) is a task that demands a lot of accuracy and reliability from the person responsible. The involvement of too many people and departments for this task as well as the paper work involved are giving a higher level of difficulty to this procedure.
This training will guide you through the drug supply from the moment that all necessary paperwork for the kind of drug and quantity is prepared for requesting it from the Drug Supply Management Department, till the time the drug is shipped to its final destination (Trial Site). We will discuss about the departments involved and their role in this procedure and give you several tips for running everything as smoothly as possible as well as effectively. Areas Covered in the Seminar: - All procedures needed for drug supply and handling in general.
- Departments involved.
- Department's role in each step.
- Tips for getting better organized and avoiding possible delays and issues
Event Details: Date: October 02, 2012 Time: 10:00 AM-11:00 AM PDT Cost: $199 per attendee per computer terminal Registration: SIgn-Up on-line now. Add to your shopping cart. |
|
|
|
|
|
|
|
Organized by:
|
|
ComplianceOnline |
|
|
Invited Speakers:
|
|
Katerina Theocharopoulou, is a Clinical Monitor Assistant (CMA). She started her career in the Clinical Trials Area through Omega Mediation Hellas (later on named SIRO Clinpharm) on 2004 as a CMA and Archive Coordinator, where she had the opportunity to collaborate with many Clinical Research Coordinators on many different clinical trials and indications such as - Hyperlipidaemia (phase IV study – 100 sites), Multiple Sclerosis (phase IIIB study – 5 sites), Neuropathitic Pain (30 sites), Benign Prostate Hyperplasia (phase III study – 17 sites), Sepsis (4 sites), HIV (phase IV study – 14 sites), Breast and Renal Cancer (phase III study –10 sites), Neovascular age-related macular degeneration (phase IV study – 8 sites) and Schizophrenia (phase IV study – 50 sites)
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2012-10-02
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702444?channel=hummolgen
|
|
|
E-mail:
|
|
referral@complianceonline.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|